Detalhe da pesquisa
1.
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Future Oncol
; 18(8): 903-913, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35073733
2.
[Using Twitter in oncology. Research, continuing education, and advocacy]. / L'uso di Twitter in oncologia. Ricerca, aggiornamento e advocacy.
Recenti Prog Med
; 106(1): 40-5, 2015 Jan.
Artigo
em Italiano
| MEDLINE | ID: mdl-25621780
3.
New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Clin Case Rep
; 9(1): 61-66, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33489133
4.
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
J Clin Oncol
; 23(30): 7660-8, 2005 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16234528
5.
Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
Clin Exp Metastasis
; 29(7): 801-5, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22752507
6.
Update on PEG-interferon α-2b as adjuvant therapy in melanoma.
Anticancer Res
; 32(9): 3901-9, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22993335
7.
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
J Clin Oncol
; 28(13): 2220-6, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20351325